$MASI
MASIMO CORP Stock $masi

$masi Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000093755622000031 Filed on February 16, 2022

Income Statement

Concept	2022 Q1	2022	2021 Q4
Revenue	$327.6M	$1.239B	$307.4M
YoY Change	11.01%	8.34%
Cost Of Revenue	$112.7M	$430.8M	$103.8M
YoY Change	4.24%	7.52%
Gross Profit	$214.9M	$808.3M	$203.7M
YoY Change	14.98%	8.79%
Gross Profit Margin	65.6%	65.23%	66.25%
Selling, General & Admin	$104.1M	$395.3M	$100.6M
YoY Change	15.29%	7.11%
% of Gross Profit	48.45%	48.9%	49.42%
Research & Development	$33.37M	$137.2M	$35.41M
YoY Change	5.28%	15.65%
% of Gross Profit	15.53%	16.98%	17.38%
Depreciation & Amortization	$9.171M	$35.62M	$6.500M
YoY Change	13.22%	21.57%
% of Gross Profit	4.27%	4.41%	3.19%
Operating Expenses	$137.5M	$532.5M	$136.1M
YoY Change	12.6%	9.29%
Operating Profit	$77.41M	$275.8M	$67.61M
YoY Change	19.46%	7.82%
Interest Expense	-$547.0K	$355.0K	$87.00K
YoY Change	-132.18%	5.03%
% of Operating Profit	-0.71%	0.13%	0.13%
Other Income/Expense, Net	-$160.0K	-$1.442M	-$78.00K
YoY Change	-260.0%	-118.22%
Pretax Income	$76.70M	$274.4M	$67.53M
YoY Change	15.0%	4.04%
Income Tax	$8.446M	$44.73M	$9.762M
% Of Pretax Income	11.01%	16.3%	14.46%
Net Earnings	$68.26M	$229.6M	$57.77M
YoY Change	-3.45%	-4.43%
Net Earnings / Revenue	20.84%	18.53%	18.79%
Basic Earnings Per Share	$1.23	$4.16	$1.05
Diluted Earnings Per Share	$1.18	$3.98	$1.00
COMMON SHARES
Basic Shares Outstanding	55.36M shares	55.17M shares	55.14M shares
Diluted Shares Outstanding		57.68M shares	57.66M shares

Balance Sheet

Concept	2022 Q1	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$745.3M	$745.3M	$652.4M
YoY Change	16.19%	16.19%
Cash & Equivalents	$745.3M	$745.3M	$652.4M
Short-Term Investments
Other Short-Term Assets	$91.03M	$47.10M	$91.77M
YoY Change	-11.12%	-24.51%
Inventory	$201.4M	$201.4M	$202.3M
Prepaid Expenses	$30.88M		$30.35M
Receivables	$200.8M	$200.8M	$191.3M
Other Receivables	$43.92M	$43.92M	$38.76M
Total Short-Term Assets	$1.238B	$1.238B	$1.138B
YoY Change	12.46%	12.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$272.8M	$303.3M	$274.9M
YoY Change	0.1%	-0.5%
Goodwill	$100.3M		$101.2M
YoY Change	-2.78%
Intangibles	$72.50M		$74.09M
YoY Change	-1.92%
Long-Term Investments	$13.83M	$13.83M	$13.93M
YoY Change	72.83%	72.88%
Other Assets	$48.58M	$80.00M	$49.89M
YoY Change	8.82%	33.77%
Total Long-Term Assets	$648.6M	$648.6M	$629.0M
YoY Change	6.09%	6.08%
TOTAL ASSETS
Total Short-Term Assets	$1.238B	$1.238B	$1.138B
Total Long-Term Assets	$648.6M	$648.6M	$629.0M
Total Assets	$1.887B	$1.887B	$1.767B
YoY Change	10.19%	10.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$75.63M	$75.63M	$60.71M
YoY Change	18.05%	17.98%
Accrued Expenses	$12.06M	$118.9M	$12.05M
YoY Change	77.52%	10.9%
Deferred Revenue	$50.90M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$15.10M
YoY Change
Total Short-Term Liabilities	$267.7M	$267.7M	$228.3M
YoY Change	14.5%	14.51%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.783M	$63.92M	$4.511M
YoY Change	-91.86%	-1.36%
Total Long-Term Liabilities	$5.783M	$63.92M	$4.511M
YoY Change	-91.86%	-1.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$267.7M	$267.7M	$228.3M
Total Long-Term Liabilities	$5.783M	$63.92M	$4.511M
Total Liabilities	$336.8M	$336.8M	$298.6M
YoY Change	10.45%	10.45%
SHAREHOLDERS EQUITY
Retained Earnings	$1.571B		$1.503B
YoY Change	17.12%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$767.7M		$767.7M
YoY Change	20.18%
Treasury Stock Shares	16.54M shares		16.54M shares
Shareholders Equity	$1.550B	$1.550B	$1.468B
YoY Change
Total Liabilities & Shareholders Equity	$1.887B	$1.887B	$1.767B
YoY Change	10.19%	10.18%

Cashflow Statement

Concept	2022 Q1	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	$68.26M	$229.6M	$57.77M
YoY Change	-3.45%	-4.43%
Depreciation, Depletion And Amortization	$9.171M	$35.62M	$6.500M
YoY Change	13.22%	21.57%
Cash From Operating Activities	$97.60M	$264.8M	$81.89M
YoY Change	51.32%	25.5%
INVESTING ACTIVITIES
Capital Expenditures	-$6.064M	$25.50M	-$11.65M
YoY Change	-57.3%	-64.85%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$0.00	$2.600M	-$2.600M
YoY Change	-100.0%	-61.48%
Cash From Investing Activities	-$6.064M	-$37.53M	-$14.25M
YoY Change	203.2%	-54.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$128.9M
YoY Change		16.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.262M	-$122.4M	9.838M
YoY Change	-104.57%	125.39%
NET CHANGE
Cash From Operating Activities	97.60M	$264.8M	81.89M
Cash From Investing Activities	-6.064M	-$37.53M	-14.25M
Cash From Financing Activities	4.262M	-$122.4M	9.838M
Net Change In Cash	95.80M	$103.4M	77.49M
YoY Change	-411.04%	34.37%
FREE CASH FLOW
Cash From Operating Activities	$97.60M	$264.8M	$81.89M
Capital Expenditures	-$6.064M	$25.50M	-$11.65M
Free Cash Flow	$103.7M	$239.3M	$93.54M
YoY Change	31.72%	72.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000937556
CY2022	masi	Grant Contract Reimbursement GrantContractReimbursement	600000	USD
CY2021	masi	Grant Contract Reimbursement GrantContractReimbursement	300000	USD
CY2019	masi	Grant Contract Reimbursement GrantContractReimbursement	600000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilities
CY2022Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilities
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1D
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P5Y
CY2021Q2	us-gaap	Revenues Revenues	299043000	USD
CY2021Q3	us-gaap	Revenues Revenues	305118000	USD
CY2021Q4	us-gaap	Revenues Revenues	307414000	USD
CY2022Q1	us-gaap	Revenues Revenues	327578000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	196875000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	192912000	USD
CY2021Q4	us-gaap	Gross Profit GrossProfit	203664000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	214896000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	65664000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	65136000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	67611000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	77411000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	53375000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	50235000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	57771000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	68258000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.97
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.91
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.00
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.18
CY2020Q1	us-gaap	Revenues Revenues	269625000	USD
CY2020Q2	us-gaap	Revenues Revenues	300953000	USD
CY2020Q3	us-gaap	Revenues Revenues	278112000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	185629000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	191584000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	178926000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	69010000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	62220000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	59698000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	64456000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	55772000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	49405000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.20
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.12
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-01-01
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-01
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-33642
CY2022	dei	Entity Registrant Name EntityRegistrantName	MASIMO CORP
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0368882
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	52 Discovery
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92618
CY2022	dei	City Area Code CityAreaCode	(949)
CY2022	dei	Local Phone Number LocalPhoneNumber	297-7000
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2022	dei	Trading Symbol TradingSymbol	MASI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Public Float EntityPublicFloat	10900000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55364690	shares
CY2022	dei	Auditor Firm AuditorFirmId	248
CY2022	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2022	dei	Auditor Location AuditorLocation	Newport Beach, California
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	745250000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	641447000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2182000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1603000	USD
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	200765000	USD
CY2021Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	141350000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	201370000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	215952000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	91027000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	102416000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1238412000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	1101165000	USD
CY2022Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73688000	USD
CY2021Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	57666000	USD
CY2022Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	28093000	USD
CY2021Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	20076000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272793000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272511000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72502000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73923000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	100334000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	103206000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	52607000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	39363000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48581000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44642000	USD
CY2022Q1	us-gaap	Assets Assets	1887010000	USD
CY2021Q1	us-gaap	Assets Assets	1712552000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	75627000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	64061000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53239000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	267736000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	70835000	USD
CY2021Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	44935000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70397000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	71601000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50877000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	233836000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	69029000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	71076000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	336765000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	304912000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.000
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55335000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55251000	shares
CY2022Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	55000	USD
CY2021Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	55000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	16539000	shares
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	15993000	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	767655000	USD
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	638736000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	752513000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	703693000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-5530000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	1413000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1570862000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1341215000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1550245000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1407640000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1887010000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1712552000	USD
CY2022	masi	Product Revenue ProductRevenue	1239153000	USD
CY2021	masi	Product Revenue ProductRevenue	1143744000	USD
CY2019	masi	Product Revenue ProductRevenue	936408000	USD
CY2022	masi	Royaltyand Other Revenue RoyaltyandOtherRevenue	0	USD
CY2021	masi	Royaltyand Other Revenue RoyaltyandOtherRevenue	0	USD
CY2019	masi	Royaltyand Other Revenue RoyaltyandOtherRevenue	1429000	USD
CY2022	us-gaap	Revenues Revenues	1239153000	USD
CY2021	us-gaap	Revenues Revenues	1143744000	USD
CY2019	us-gaap	Revenues Revenues	937837000	USD
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	430806000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	400679000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	308665000	USD
CY2022	us-gaap	Gross Profit GrossProfit	808347000	USD
CY2021	us-gaap	Gross Profit GrossProfit	743065000	USD
CY2019	us-gaap	Gross Profit GrossProfit	629172000	USD
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	395291000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	369057000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	314661000	USD
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	137234000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118659000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93295000	USD
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	474000	USD
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2022	us-gaap	Operating Expenses OperatingExpenses	532525000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	487242000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	407956000	USD
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	275822000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	255823000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	221216000	USD
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1442000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7913000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12950000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	274380000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	263736000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	234166000	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44733000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23454000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37950000	USD
CY2022	us-gaap	Profit Loss ProfitLoss	229647000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	240282000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	196216000	USD
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.39
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.67
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.98
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.14
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.44
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55166000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54700000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53434000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57682000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58037000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57100000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	229647000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	240282000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	196216000	USD
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6943000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	8131000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-519000	USD
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	222704000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	248413000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	195697000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	969065000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28349000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	123000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39235000	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37554000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	196216000	USD
CY2019	us-gaap	Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple	-26795000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-519000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1167874000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63036000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3807000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42225000	USD
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	110540000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	240282000	USD
CY2021	us-gaap	Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple	439000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	8131000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1407640000	USD
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20924000	USD
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	16728000	USD
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44624000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-6943000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1550245000	USD
CY2022	us-gaap	Profit Loss ProfitLoss	229647000	USD
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	128919000	USD
CY2022	us-gaap	Profit Loss ProfitLoss	229647000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	240282000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	196216000	USD
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35620000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29300000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23487000	USD
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	44624000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	42225000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	39235000	USD
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-479000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-554000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-357000	USD
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	815000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	82000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	687000	USD
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15086000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4964000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5965000	USD
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	60799000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2229000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23580000	USD
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13493000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	94434000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21257000	USD
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6884000	USD
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	29984000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	8536000	USD
CY2022	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-16061000	USD
CY2021	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-7749000	USD
CY2019	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-11958000	USD
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	8053000	USD
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	2806000	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-3308000	USD
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-57000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1320000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	226000	USD
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10988000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7637000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9934000	USD
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	47000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	15544000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5338000	USD
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7110000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10871000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7739000	USD
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6409000	USD
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1301000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	4079000	USD
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7793000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9391000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	746000	USD
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	787000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-136000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2038000	USD
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	264754000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	210963000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	221642000	USD
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	120000000	USD
CY2019	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	160000000	USD
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	280000000	USD
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25503000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72549000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68375000	USD
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9426000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7408000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4117000	USD
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	112706000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2022	masi	Deposit To Acquire Noncontrolling Interest DepositToAcquireNoncontrollingInterest	0	USD
CY2021	masi	Deposit To Acquire Noncontrolling Interest DepositToAcquireNoncontrollingInterest	3374000	USD
CY2019	masi	Deposit To Acquire Noncontrolling Interest DepositToAcquireNoncontrollingInterest	0	USD
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2600000	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6750000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5189000	USD
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37529000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82787000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-197681000	USD
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23241000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58424000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28339000	USD
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	128917000	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	110540000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	37555000	USD
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16728000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2191000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	123000	USD
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-122404000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-54307000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9339000	USD
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1448000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3060000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	812000	USD
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103373000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	76929000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568075000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15434000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	645004000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568075000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	552641000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	748377000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	645004000	USD
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Company </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes and reduce the cost of patient care. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invented Masimo Signal Extraction Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which provides the capabilities of Measure-through Motion and Low Perfusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pulse oximetry to address the primary limitations of conventional pulse oximetry. Over the years, the Company’s product offerings have expanded significantly to also include rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pulse CO-Oximetry, with its ability to monitor carboxyhemoglobin (SpCO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), methemoglobin (SpMet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), total hemoglobin concentration (SpHb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), fractional arterial oxygen saturation (SpfO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Oxygen Content (SpOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Pleth Variability Index (PVi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pleth Variability Index (RPVi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), respiration rate from the pleth (RRp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and Oxygen Reserve Index (ORi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); as well as acoustic respiration monitoring (RRa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), SedLine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brain function monitoring, NomoLine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capnography and gas monitoring and O3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regional Oximetry. These technologies are based upon Masimo SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other proprietary algorithms and are incorporated into a variety of product platforms depending on customers’ specifications. The Company’s current technology offerings also include remote patient monitoring, connectivity, and hospital automation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solutions, including Masimo Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Surveillance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo SafetyNet-Open</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Replica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Iris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MyView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UniView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uniview : 60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo Sleep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Centroid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Bridge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company’s technologies are supported by a substantial intellectual property portfolio that the Company has built through internal development and, to a lesser extent, acquisitions and license agreements.</span></div>
CY2022	us-gaap	Fiscal Period FiscalPeriod	<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 was a 52 week fiscal year ended January 1, 2022, with the fourth quarter having 13 weeks. All references to years in these notes to consolidated financial statements are references to fiscal years unless otherwise noted.</span></div>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div>
CY2022	masi	Numberof Sourcesof Product Revenue NumberofSourcesofProductRevenue	4	segment
CY2022	masi	Royalty Revenue Numberof Days Royalty Revenueis Adjusted Subsequentto Quarter End RoyaltyRevenueNumberofDaysRoyaltyRevenueisAdjustedSubsequenttoQuarterEnd	P60D
CY2022	masi	Royalty Royalty	0	USD
CY2021	masi	Royalty Royalty	0	USD
CY2019	masi	Royalty Royalty	700000	USD
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2740000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3395000	USD
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1910000	USD
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2219000	USD
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	832000	USD
CY2019	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1715000	USD
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	1439000	USD
CY2021	us-gaap	Product Warranty Expense ProductWarrantyExpense	196000	USD
CY2019	us-gaap	Product Warranty Expense ProductWarrantyExpense	1130000	USD
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1033000	USD
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1683000	USD
CY2019	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1360000	USD
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2487000	USD
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2740000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3395000	USD
CY2022	us-gaap	Advertising Expense AdvertisingExpense	9000000	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	30800000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	14000000	USD
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2516000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	229647000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	240282000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	196216000	USD
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55166000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54700000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53434000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.39
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.67
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55166000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54700000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53434000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3337000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3666000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57682000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58037000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57100000	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.98
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.14
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.44
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
CY2022	us-gaap	Interest Paid Net InterestPaidNet	285000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	270000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	211000	USD
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	43947000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	39491000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6276000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	42270000	USD
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7306000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	6676000	USD
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6042000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15387000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	26484000	USD
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2053000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6686000	USD
CY2022	masi	Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise	0	USD
CY2021	masi	Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise	5100000	USD
CY2019	masi	Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise	0	USD
CY2022	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	694000	USD
CY2021	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	3011000	USD
CY2019	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	14000	USD
CY2022	masi	Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice	0	USD
CY2021	masi	Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice	1616000	USD
CY2019	masi	Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	745250000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	641447000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	567687000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	3127000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	3557000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	388000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	748377000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	645004000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568075000	USD
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Rou Assetsand Lease Liabilities CumulativeEffectonRetainedEarningsNetofTaxROUAssetsandLeaseLiabilities	22500000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Lease Receivable CumulativeEffectonRetainedEarningsNetofTaxLeaseReceivable	62000000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Leased Equipment CumulativeEffectonRetainedEarningsNetofTaxLeasedEquipment	103500000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Deferred Tax Assets CumulativeEffectonRetainedEarningsNetofTaxDeferredTaxAssets	8600000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Deferred Tax Deferred Revenueand Contract Related Liabilities CumulativeEffectonRetainedEarningsNetofTaxDeferredTaxDeferredRevenueandContractRelatedLiabilities	9100000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Other Current Liabilities CumulativeEffectonRetainedEarningsNetofTaxOtherCurrentLiabilities	3000000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	128319000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	133098000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17140000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15985000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	55911000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	66869000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	201370000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	215952000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30879000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30235000	USD
CY2022Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28666000	USD
CY2021Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	23206000	USD
CY2022Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	12847000	USD
CY2021Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	14545000	USD
CY2022Q1	us-gaap	Prepaid Taxes PrepaidTaxes	7009000	USD
CY2021Q1	us-gaap	Prepaid Taxes PrepaidTaxes	14782000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	3041000	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	3397000	USD
CY2022Q1	us-gaap	Prepaid Royalties PrepaidRoyalties	2785000	USD
CY2021Q1	us-gaap	Prepaid Royalties PrepaidRoyalties	3081000	USD
CY2022Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2410000	USD
CY2021Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2283000	USD
CY2022Q1	us-gaap	Deposit Assets DepositAssets	0	USD
CY2021Q1	us-gaap	Deposit Assets DepositAssets	3374000	USD
CY2022Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	3390000	USD
CY2021Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	7513000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	91027000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	102416000	USD
CY2022	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	59400000	USD
CY2021	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	42600000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	102609000	USD
CY2021Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	81074000	USD
CY2022Q1	masi	Salestypelease Allowancefor Credit Loss SalestypeleaseAllowanceforCreditLoss	255000	USD
CY2021Q1	masi	Salestypelease Allowancefor Credit Loss SalestypeleaseAllowanceforCreditLoss	202000	USD
CY2022Q1	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	102354000	USD
CY2021Q1	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	80872000	USD
CY2022Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28666000	USD
CY2021Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	23206000	USD
CY2022Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73688000	USD
CY2021Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	57666000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	28666000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	24297000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	20552000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears	14428000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears	7993000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter	6418000	USD
CY2021Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	20076000	USD
CY2022Q1	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	102354000	USD
CY2022Q1	masi	Deferred Sales Commissions DeferredSalesCommissions	11878000	USD
CY2021Q1	masi	Deferred Sales Commissions DeferredSalesCommissions	7477000	USD
CY2022Q1	masi	Deferred Cost Of Goods Sold DeferredCostOfGoodsSold	8598000	USD
CY2021Q1	masi	Deferred Cost Of Goods Sold DeferredCostOfGoodsSold	7336000	USD
CY2022Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4970000	USD
CY2021Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3925000	USD
CY2022Q1	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	2647000	USD
CY2021Q1	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	1338000	USD
CY2022Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	28093000	USD
CY2022	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	500000	USD
CY2021	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	400000	USD
CY2021Q1	masi	Deferred Costof Goods Sold Accumulated Amortization DeferredCostofGoodsSoldAccumulatedAmortization	900000	USD
CY2019	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	1000000	USD
CY2022Q1	masi	Deferred Costof Goods Sold Accumulated Amortization DeferredCostofGoodsSoldAccumulatedAmortization	500000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	430294000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	406647000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	157501000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	134136000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272793000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272511000	USD
CY2022	us-gaap	Depreciation Depreciation	25300000	USD
CY2021	us-gaap	Depreciation Depreciation	21800000	USD
CY2019	us-gaap	Depreciation Depreciation	19100000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	118529000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	110589000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	46027000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36666000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72502000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	73923000	USD
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2022Q1	masi	Finite Lived Patents Gross Not Amortized FiniteLivedPatentsGrossNotAmortized	9000000	USD
CY2021Q1	masi	Finite Lived Patents Gross Not Amortized FiniteLivedPatentsGrossNotAmortized	8200000	USD
CY2022Q1	masi	Finite Lived Trademarks Gross Not Amortized FiniteLivedTrademarksGrossNotAmortized	1000000	USD
CY2021Q1	masi	Finite Lived Trademarks Gross Not Amortized FiniteLivedTrademarksGrossNotAmortized	900000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8242000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8138000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7674000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6864000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	5930000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	35654000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72502000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	103206000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	22350000	USD
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	USD
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	79862000	USD
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2872000	USD
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	994000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	100334000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	103206000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30486000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32324000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6371000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5975000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26290000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28373000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	32661000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	34348000	USD
CY2022Q1	masi	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	15200000	USD
CY2021Q1	masi	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	9200000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7411000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6685000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5235000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3991000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2804000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9442000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	35568000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2907000	USD
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8200000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	6900000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	6800000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	318000000	USD
CY2022Q1	us-gaap	Equity Method Investments EquityMethodInvestments	13830000	USD
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	8002000	USD
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3863000	USD
CY2021Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3816000	USD
CY2022Q1	us-gaap	Nontrade Receivables Noncurrent NontradeReceivablesNoncurrent	402000	USD
CY2021Q1	us-gaap	Nontrade Receivables Noncurrent NontradeReceivablesNoncurrent	500000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48581000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44642000	USD
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	35127000	USD
CY2021Q1	us-gaap	Deferred Revenue DeferredRevenue	33221000	USD
CY2022Q1	masi	Accruedrebatesandallowances Accruedrebatesandallowances	13628000	USD
CY2021Q1	masi	Accruedrebatesandallowances Accruedrebatesandallowances	12127000	USD
CY2022Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7424000	USD
CY2021Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	3829000	USD
CY2022Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	56179000	USD
CY2021Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	49177000	USD
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5302000	USD
CY2021Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4242000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50877000	USD
CY2021Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	44935000	USD
CY2021Q1	us-gaap	Deferred Revenue DeferredRevenue	33221000	USD
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	31133000	USD
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	29227000	USD
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	35127000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1165100000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	16302000	USD
CY2021Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	14365000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12061000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6794000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	11996000	USD
CY2021Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5910000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	7136000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	4058000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6371000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5975000	USD
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5618000	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3655000	USD
CY2022Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2487000	USD
CY2021Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2740000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1989000	USD
CY2021Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1682000	USD
CY2022Q1	masi	Accrued Donations Current AccruedDonationsCurrent	1707000	USD
CY2021Q1	masi	Accrued Donations Current AccruedDonationsCurrent	495000	USD
CY2022Q1	masi	Minority Interest Current Liabilities MinorityInterestCurrentLiabilities	0	USD
CY2021Q1	masi	Minority Interest Current Liabilities MinorityInterestCurrentLiabilities	3469000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4730000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4096000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70397000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53239000	USD
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1700000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26290000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28373000	USD
CY2022Q1	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	16980000	USD
CY2021Q1	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	19245000	USD
CY2022Q1	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	14864000	USD
CY2021Q1	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	11777000	USD
CY2022Q1	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	5112000	USD
CY2021Q1	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	6247000	USD
CY2022Q1	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	5783000	USD
CY2021Q1	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	5434000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	69029000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	71076000	USD
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1300000	shares
CY2022	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	546000	shares
CY2021	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	456000	shares
CY2019	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	275000	shares
CY2022	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	235.88
CY2021	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	242.40
CY2019	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	136.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	44600000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	42200000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	39200000	USD
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10600000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3448000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.44
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5212000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.23
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5676000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	43.61
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	85000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	250.15
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	187.83
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	140.56
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	171000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	149.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	219000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	126.98
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	158000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	83.14
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.80
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	32.41
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	391000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	53.55
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1945000	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	851000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	33.32
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2971000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	81.38
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3448000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.44
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5212000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.23
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2175000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	57.09
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2026000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	47.31
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3311000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2971000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M9D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2175000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3448000	shares
CY2022	masi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Price Below Market Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermPriceBelowMarketValue	P5Y1M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2026000	shares
CY2021	masi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Price Below Market Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermPriceBelowMarketValue	P5Y10M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y3M18D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y8M12D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	three
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	three
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	three years
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.009
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.002
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.026
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.309
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.347
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.269
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.355
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.282
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.300
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	75.72
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	628100000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14200000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	51.10
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.29
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	15200000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	15100000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	512500000	USD
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	84700000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	355300000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	93900000	USD
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	16400000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	30400000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	15700000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-86000	USD
CY2022	us-gaap	Interest Income Other InterestIncomeOther	936000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	5534000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	13917000	USD
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1863000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2631000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-627000	USD
CY2022	us-gaap	Interest Expense InterestExpense	355000	USD
CY2021	us-gaap	Interest Expense InterestExpense	338000	USD
CY2019	us-gaap	Interest Expense InterestExpense	328000	USD
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	160000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12950000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1442000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7913000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	221225000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	214816000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	181664000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	53155000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	48920000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	52502000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	274380000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	263736000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	234166000	USD
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	38166000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	13901000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	30218000	USD
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7069000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6444000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5273000	USD
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14584000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	8073000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	8424000	USD
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	59819000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	28418000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	43915000	USD
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4884000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1354000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3732000	USD
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-6054000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-6191000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1985000	USD
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4148000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-127000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-248000	USD
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15086000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4964000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5965000	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44733000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23454000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37950000	USD
CY2022	masi	Tax And Accrued Interest Related To Uncertain Tax Positions Increase Decrease TaxAndAccruedInterestRelatedToUncertainTaxPositionsIncreaseDecrease	3600000	USD
CY2021	masi	Tax And Accrued Interest Related To Uncertain Tax Positions Increase Decrease TaxAndAccruedInterestRelatedToUncertainTaxPositionsIncreaseDecrease	200000	USD
CY2019	masi	Tax And Accrued Interest Related To Uncertain Tax Positions Increase Decrease TaxAndAccruedInterestRelatedToUncertainTaxPositionsIncreaseDecrease	-1800000	USD
CY2021Q1	masi	Operating Lease Assets OperatingLeaseAssets	5782000	USD
CY2022	masi	Statutory Regular Federal Income Tax Rate StatutoryRegularFederalIncomeTaxRate	0.210
CY2021	masi	Statutory Regular Federal Income Tax Rate StatutoryRegularFederalIncomeTaxRate	0.210
CY2019	masi	Statutory Regular Federal Income Tax Rate StatutoryRegularFederalIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.022
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.017
CY2022	masi	U.S.Taxonforeignincomenet U.S.Taxonforeignincomenet	0.009
CY2021	masi	U.S.Taxonforeignincomenet U.S.Taxonforeignincomenet	0.010
CY2019	masi	U.S.Taxonforeignincomenet U.S.Taxonforeignincomenet	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.055
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.104
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.060
CY2022	masi	Effective Income Tax Rate Reconciliation Tax Credit Derecognitionofuncertaintaxposition EffectiveIncomeTaxRateReconciliationTaxCreditDerecognitionofuncertaintaxposition	-0.010
CY2021	masi	Effective Income Tax Rate Reconciliation Tax Credit Derecognitionofuncertaintaxposition EffectiveIncomeTaxRateReconciliationTaxCreditDerecognitionofuncertaintaxposition	-0.022
CY2019	masi	Effective Income Tax Rate Reconciliation Tax Credit Derecognitionofuncertaintaxposition EffectiveIncomeTaxRateReconciliationTaxCreditDerecognitionofuncertaintaxposition	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.007
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.163
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.089
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.162
CY2019	masi	Tax Cutsand Jobs Act Income Tax Expense Benefit TaxCutsandJobsActIncomeTaxExpenseBenefit	900000	USD
CY2022Q1	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	267100000	USD
CY2022Q1	masi	Tax Cutsand Jobs Act Deferred Tax Liability Undistributed Foreign Earnings TaxCutsandJobsActDeferredTaxLiabilityUndistributedForeignEarnings	86500000	USD
CY2022	masi	Tax Cutsand Jobs Act Deferred Tax Liability Foreign Withholding Tax TaxCutsandJobsActDeferredTaxLiabilityForeignWithholdingTax	1600000	USD
CY2022Q1	masi	Tax Cutsand Jobs Act Deferred Tax Liability Not Recognized Amountof Unrecognized Deferred Tax Liability Undistributed Earningsof Foreign Subsidiary TaxCutsandJobsActDeferredTaxLiabilityNotRecognizedAmountofUnrecognizedDeferredTaxLiabilityUndistributedEarningsofForeignSubsidiary	180600000	USD
CY2022	masi	Tax Cutsand Jobs Act Unrecognized Deferred Tax Liability Potential Foreign Withholding Tax TaxCutsandJobsActUnrecognizedDeferredTaxLiabilityPotentialForeignWithholdingTax	8600000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	26139000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	19769000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9494000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19140000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	19165000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	16534000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	13079000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9398000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8919000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8385000	USD
CY2022Q1	masi	Operating Lease Assets OperatingLeaseAssets	5696000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	USD
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	82492000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79008000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6524000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15660000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	75968000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	63348000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12966000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12818000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2649000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	5465000	USD
CY2022Q1	masi	Operating Lease Liabilities OperatingLeaseLiabilities	5436000	USD
CY2021Q1	masi	Operating Lease Liabilities OperatingLeaseLiabilities	5429000	USD
CY2022Q1	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	2829000	USD
CY2021Q1	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	3108000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	4265000	USD
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3400000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	2302000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	440000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1110000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	28585000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	30232000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	47383000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	33116000	USD
CY2022	masi	Indefinitely Carryforward Research And Development Credits IndefinitelyCarryforwardResearchAndDevelopmentCredits	19200000	USD
CY2022	us-gaap	Investment Tax Credit InvestmentTaxCredit	300000	USD
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9100000	USD
CY2022	masi	Foreign Tax Expense Benefit Businessand Employment Actions ForeignTaxExpenseBenefitBusinessandEmploymentActions	-1000000	USD
CY2019	masi	Foreign Tax Expense Benefit Businessand Employment Actions ForeignTaxExpenseBenefitBusinessandEmploymentActions	-900000	USD
CY2021	masi	Earnings Per Share Diluted Effectof Foreign Tax Benefit Relatingto Businessand Employment Actions EarningsPerShareDilutedEffectofForeignTaxBenefitRelatingtoBusinessandEmploymentActions	0.02
CY2022	masi	Earnings Per Share Diluted Effectof Foreign Tax Benefit Relatingto Businessand Employment Actions EarningsPerShareDilutedEffectofForeignTaxBenefitRelatingtoBusinessandEmploymentActions	0.02
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2019Q4	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18005000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17009000	USD
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	543000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	471000	USD
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	850000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7019000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6565000	USD
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3069000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	6040000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21648000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18005000	USD
CY2022Q1	masi	Amount Of Unrecognized Benefits Affecting Future Tax Rate AmountOfUnrecognizedBenefitsAffectingFutureTaxRate	19800000	USD
CY2021Q1	masi	Amount Of Unrecognized Benefits Affecting Future Tax Rate AmountOfUnrecognizedBenefitsAffectingFutureTaxRate	16300000	USD
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	100000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	800000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	500000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3200000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	800000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	700000	USD
CY2022Q1	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	5000000	USD
CY2022Q1	masi	Licensefee Changein Control LicensefeeChangeinControl	2500000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2500000	USD
CY2022Q1	masi	Severance Plan Participation Agreements SeverancePlanParticipationAgreements	5	Agreement
CY2022	masi	Supplemental Unemployment Benefits Severance Benefits Required Noticeof Resignation SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation	P6M
CY2022Q1	masi	Royalty Guarantees Commitments Changein Control RoyaltyGuaranteesCommitmentsChangeinControl	15000000	USD
CY2022Q1	masi	Royalty Guarantees Commitments Additional Changein Control RoyaltyGuaranteesCommitmentsAdditionalChangeinControl	2000000	USD
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	170200000	USD
CY2022Q1	us-gaap	Cash Cash	745300000	USD
CY2022Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	5100000	USD
CY2022Q1	masi	Concentration Risk Ar Customer ConcentrationRiskARCustomer	1	Customer
CY2021Q1	masi	Concentration Risk Ar Customer ConcentrationRiskARCustomer	1	Customer
CY2022Q1	masi	Royalty Agreement RoyaltyAgreement	1
CY2022	masi	Royalty Royalty	0	USD
CY2021	masi	Royalty Royalty	0	USD
CY2019	masi	Royalty Royalty	700000	USD
CY2019Q3	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	10500000	USD
CY2021Q1	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	219926000	USD
CY2022	masi	Product Revenue ProductRevenue	1239153000	USD
CY2022	masi	Percentage Of Product Revenue Based On Geographic Area By Destination PercentageOfProductRevenueBasedOnGeographicAreaByDestination	1.000
CY2021	masi	Product Revenue ProductRevenue	1143744000	USD
CY2021	masi	Percentage Of Product Revenue Based On Geographic Area By Destination PercentageOfProductRevenueBasedOnGeographicAreaByDestination	1.000
CY2019	masi	Product Revenue ProductRevenue	936408000	USD
CY2019	masi	Percentage Of Product Revenue Based On Geographic Area By Destination PercentageOfProductRevenueBasedOnGeographicAreaByDestination	1.000
CY2022Q1	us-gaap	Noncurrent Assets NoncurrentAssets	275440000	USD
CY2022Q1	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000
CY2021Q1	us-gaap	Noncurrent Assets NoncurrentAssets	273849000	USD

Files In Submission

Name	View Source	Status
0000937556-22-000031-index-headers.html	Edgar Link	pending
0000937556-22-000031-index.html	Edgar Link	pending
0000937556-22-000031.txt	Edgar Link	pending
0000937556-22-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
formofcommonstocknewcert.htm	Edgar Link	pending
formofcommonstocknewcert001.jpg	Edgar Link	pending
formofcommonstocknewcert002.jpg	Edgar Link	pending
masi-20220101.htm	Edgar Link	pending
masi-20220101.xsd	Edgar Link	pending
masi-20220101x10kex1037.htm	Edgar Link	pending
masi-20220101x10kex211.htm	Edgar Link	pending
masi-20220101x10kex231.htm	Edgar Link	pending
masi-20220101x10kex311.htm	Edgar Link	pending
masi-20220101x10kex312.htm	Edgar Link	pending
masi-20220101x10kex321.htm	Edgar Link	pending
masi-20220101_cal.xml	Edgar Link	unprocessable
masi-20220101_def.xml	Edgar Link	unprocessable
masi-20220101_g1.jpg	Edgar Link	pending
masi-20220101_g10.jpg	Edgar Link	pending
masi-20220101_g11.jpg	Edgar Link	pending
masi-20220101_g12.jpg	Edgar Link	pending
masi-20220101_g13.jpg	Edgar Link	pending
masi-20220101_g14.jpg	Edgar Link	pending
masi-20220101_g15.jpg	Edgar Link	pending
masi-20220101_g16.jpg	Edgar Link	pending
masi-20220101_g17.jpg	Edgar Link	pending
masi-20220101_g18.jpg	Edgar Link	pending
masi-20220101_g19.jpg	Edgar Link	pending
masi-20220101_g2.jpg	Edgar Link	pending
masi-20220101_g20.jpg	Edgar Link	pending
masi-20220101_g21.jpg	Edgar Link	pending
masi-20220101_g22.jpg	Edgar Link	pending
masi-20220101_g23.jpg	Edgar Link	pending
masi-20220101_g24.jpg	Edgar Link	pending
masi-20220101_g25.jpg	Edgar Link	pending
masi-20220101_g26.jpg	Edgar Link	pending
masi-20220101_g27.jpg	Edgar Link	pending
masi-20220101_g28.jpg	Edgar Link	pending
masi-20220101_g29.jpg	Edgar Link	pending
masi-20220101_g3.jpg	Edgar Link	pending
masi-20220101_g30.jpg	Edgar Link	pending
masi-20220101_g31.jpg	Edgar Link	pending
masi-20220101_g32.jpg	Edgar Link	pending
masi-20220101_g33.jpg	Edgar Link	pending
masi-20220101_g34.jpg	Edgar Link	pending
masi-20220101_g35.jpg	Edgar Link	pending
masi-20220101_g36.jpg	Edgar Link	pending
masi-20220101_g37.jpg	Edgar Link	pending
masi-20220101_g38.jpg	Edgar Link	pending
masi-20220101_g4.jpg	Edgar Link	pending
masi-20220101_g5.jpg	Edgar Link	pending
masi-20220101_g6.jpg	Edgar Link	pending
masi-20220101_g7.jpg	Edgar Link	pending
masi-20220101_g8.jpg	Edgar Link	pending
masi-20220101_g9.jpg	Edgar Link	pending
masi-20220101_htm.xml	Edgar Link	completed
masi-20220101_lab.xml	Edgar Link	unprocessable
masi-20220101_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MASI
MASIMO CORP Stock $masi

2022 Q1 Form 10-K Financial Statement

#000093755622000031 Filed on February 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI MASIMO CORP Stock $masi

2022 Q1 Form 10-K Financial Statement

#000093755622000031 Filed on February 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI
MASIMO CORP Stock $masi